Raymond James & Associates Athersys, Inc Transaction History

Raymond James & Associates

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	BUY	$0.18 - $0.86 $1,818 - $8,686	10,100 New	10,100 $3,000
Q4 2021 Feb 08, 2022	SELL	$0.85 - $1.4 $11,985 - $19,740	-14,100 Closed	0 $0
Q3 2021 Nov 02, 2021	SELL	$1.33 - $1.77 $5,254 - $6,993	-3,951 Reduced 21.89%	14,100 $19,000
Q2 2021 Aug 11, 2021	BUY	$1.41 - $1.94 $2,820 - $3,880	2,000 Added 12.46%	18,051 $26,000
Q1 2021 May 14, 2021	SELL	$1.61 - $2.77 $11,949 - $20,558	-7,422 Reduced 31.62%	16,051 $29,000
Q4 2020 Feb 12, 2021	BUY	$1.55 - $2.24 $15,453 - $22,332	9,970 Added 73.84%	23,473 $41,000
Q3 2020 Nov 04, 2020	BUY	$1.91 - $3.08 $4,249 - $6,853	2,225 Added 19.73%	13,503 $26,000
Q2 2020 Jul 28, 2020	SELL	$1.97 - $3.98 $3,136 - $6,336	-1,592 Reduced 12.37%	11,278 $31,000
Q1 2020 Apr 21, 2020	SELL	$1.17 - $3.0 $5,557 - $14,250	-4,750 Reduced 26.96%	12,870 $39,000
Q2 2019 Aug 06, 2019	BUY	$1.39 - $2.03 $9,035 - $13,194	6,500 Added 58.45%	17,620 $30,000
Q4 2018 Feb 11, 2019	BUY	$1.41 - $2.16 $282 - $432	200 Added 1.83%	11,120 $16,000
Q1 2018 May 14, 2018	BUY	$1.34 - $2.03 $670 - $1,014	500 Added 4.8%	10,920 $20,000
Q4 2017 Feb 14, 2018	SELL	$1.65 - $2.45 $8,250 - $12,250	-5,000 Reduced 32.43%	10,420 $19,000
Q3 2017 Nov 13, 2017	BUY	$1.5 - $2.55 $4,500 - $7,649	3,000 Added 24.15%	15,420 $32,000
Q2 2017 Aug 14, 2017	BUY	N/A	12,420	12,420 $19,000

Ticker ATHX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 305,110,016
Market Cap $3.05M
Description
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product i...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.